Skip to main content
Clinical Trials/DRKS00022991
DRKS00022991RecruitingNot Applicable

Immune cell profiles in the blood in children, adolescents and adults with tuberous sclerosis complex disease and their correlation with organ manifestations and treatment response to immunotherapy with mTOR inhibitors

niversitätsklinikum Münster0 sites90 target enrollmentStarted: September 23, 2020Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
one to one (—)
Sex
All

Inclusion Criteria

  • Children and adults; clinically and / or molecular-genetic (from the blood) confirmed tuberous sclerosis with epilepsy.
  • Control group: epilepsy without evidence of tuberous sclerosis; People with no evidence of a neurological disease

Exclusion Criteria

  • Current immunotherapy except mTOR inhibitor therapy (everolimus, sirolimus) (control group of healthy people and people with epilepsy without tuberous sclerosis: also excluded when taking everolimus, sirolimus); current infection; comorbid autoimmune disease

Investigators

Sponsor
niversitätsklinikum Münster

Similar Trials